Cyclin-dependent kinase activity is required for type I interferon production

被引:38
作者
Cingoz, Oya [1 ,2 ]
Goff, Stephen P. [1 ,2 ,3 ]
机构
[1] Columbia Univ, Med Ctr, Dept Biochem & Mol Biophys, New York, NY 10032 USA
[2] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA
[3] Columbia Univ, Med Ctr, Howard Hughes Med Inst, New York, NY 10032 USA
关键词
type I interferon; IFN-stimulated genes; cyclin-dependent kinases; CDK inhibitors; translational regulation; BETA MESSENGER-RNA; HUMAN TUMOR XENOGRAFTS; BREAST-CANCER; GENE-EXPRESSION; NUCLEIC-ACIDS; CYTOSOLIC DNA; GMP-AMP; INHIBITOR; PHOSPHORYLATION; RECEPTOR;
D O I
10.1073/pnas.1720431115
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recognition of nucleic acids results in the production of type I IFNs, which activate the JAK/STAT pathway and promote the expression of IFN-stimulated genes. In a search for modulators of this pathway, we discovered an unexpected requirement for cyclin-dependent kinases (CDK) in the production of type I IFN following nucleic acid sensing and virus infection. Inhibition of CDK activity or knockdown of CDK levels leads to a striking block in STAT activation and IFN-stimulated gene expression. CDKs are not required for the initial nucleic acid sensing leading to IFN-beta mRNA induction, nor for the response to exogenous IFN-alpha/beta, but are critical for IFN-beta release into culture supernatants, suggesting a posttranscriptional role for CDKs in type I IFN production. In the absence of CDK activity, we demonstrate a translational block specific for IFN-beta, in which IFN-beta mRNA is removed from the actively translating polysomes, while the distribution of other cellular mRNAs or global translation rates are unaffected. Our findings reveal a critical role for CDKs in the translation of IFN-beta.
引用
收藏
页码:E2950 / E2959
页数:10
相关论文
共 44 条
[1]   High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line [J].
Adati N. ;
Huang M.-C. ;
Suzuki T. ;
Suzuki H. ;
Kojima T. .
BMC Research Notes, 2 (1)
[2]   Nucleic Acid Sensing and Innate Immunity: Signaling Pathways Controlling Viral Pathogenesis and Autoimmunity [J].
Ahlers L.R.H. ;
Goodman A.G. .
Current Clinical Microbiology Reports, 2016, 3 (3) :132-141
[3]   CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response [J].
Bancerek, Joanna ;
Poss, Zachary C. ;
Steinparzer, Iris ;
Sedlyarov, Vitaly ;
Pfaffenwimmer, Thaddaeus ;
Mikulic, Ivana ;
Doelken, Lars ;
Strobl, Birgit ;
Mueller, Mathias ;
Taatjes, Dylan J. ;
Kovarik, Pavel .
IMMUNITY, 2013, 38 (02) :250-262
[4]   AU-rich elements and associated factors: are there unifying principles? [J].
Barreau, C ;
Paillard, L ;
Osborne, HB .
NUCLEIC ACIDS RESEARCH, 2005, 33 (22) :7138-7150
[5]   FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J].
Beaver, Julia A. ;
Amiri-Kordestani, Laleh ;
Charlab, Rosane ;
Chen, Wei ;
Palmby, Todd ;
Tilley, Amy ;
Zirkelbach, Jeanne Fourie ;
Yu, Jingyu ;
Liu, Qi ;
Zhao, Liang ;
Crich, Joyce ;
Chen, Xiao Hong ;
Hughes, Minerva ;
Bloomquist, Erik ;
Tang, Shenghui ;
Sridhara, Rajeshwari ;
Kluetz, Paul G. ;
Kim, Geoffrey ;
Ibrahim, Amna ;
Pazdur, Richard ;
Cortazar, Patricia .
CLINICAL CANCER RESEARCH, 2015, 21 (21) :4760-4766
[6]   Cell-specific responses to loss of cyclin-dependent kinases [J].
Berthet, C. ;
Kaldis, P. .
ONCOGENE, 2007, 26 (31) :4469-4477
[7]  
Bor Y.C., 2006, NAT PROTOC
[8]   AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts [J].
Byth, Kate F. ;
Thomas, Andrew ;
Hughes, Gareth ;
Forder, Cheryl ;
McGregor, Alexandra ;
Geh, Catherine ;
Oakes, Sandra ;
Green, Clive ;
Walker, Mike ;
Newcombe, Nicholas ;
Green, Stephen ;
Growcott, Jim ;
Barker, Andy ;
Wilkinson, Robert W. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) :1856-1866
[9]   Identification of CDK2 substrates in human cell lysates [J].
Chi, Yong ;
Welcker, Markus ;
Hizli, Asli A. ;
Posakony, Jeffrey J. ;
Aebersold, Ruedi ;
Clurman, Bruce E. .
GENOME BIOLOGY, 2008, 9 (10)
[10]   SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples [J].
Conroy, Andrew ;
Stockett, David E. ;
Walker, Duncan ;
Arkin, Michelle R. ;
Hoch, Ute ;
Fox, Judith A. ;
Hawtin, Rachael Elizabeth .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) :723-732